Table 4.
SphK/S1P/S1PR drugs in clinical trials related to cancer treatment (Adapted from [12]).
| Drug | SphK Selectivity | Indications | ClinicalTrials.gov Identifier | Phase |
|---|---|---|---|---|
| Safingol | Sphingosine derivative, PKC inhibitor | Solid tumors, combined with fenretinide Solid tumors, combined with cisplatin |
NCT01553071 NCT00084812 |
I (Recruiting) I (Completed) |
| ABC294640 | SPHK2 inhibitor | Pancreatic cancer | NCT01488513 | I (Completed) |
| Diffuse Large B Cell- | NCT02229981 | I (Recruiting) | ||
| Lymphoma | ||||
| Kaposi Sarcoma | NCT02229981 | II (Recruiting) | ||
| Multiple Myeloma | NCT02757326 | Ib/II (Recruiting) | ||
| Carcinoma, Hepatocellular | NCT02939807 | II (Recruiting) | ||
| Sonepcizumab (ASONEP) | S1P-specific monoclonal antibody | Advanced Solid tumors Renal Cell Carcinoma |
NCT00661414 NCT01762033 |
I (Completed) II (Terminated) |
| Fingolimod | S1PR antagonist | Glioblastoma | NCT02490930 | I (Recruiting) |